The publicly listed company Liminatus Pharma plans to raise $500 million to invest in BNB
ChainCatcher news, according to businessinsider, the clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) announced today its plan to strategically expand into the cryptocurrency and blockchain sectors.
The company intends to establish a subsidiary named "American BNB Strategy" to lead its digital asset investment and management initiatives. Through this platform, Liminatus plans to raise and deploy up to $500 million in a phased manner, aiming for strategic long-term investments in BNB.
Liminatus emphasizes that while the company remains fully committed to its core business—advancing cancer treatment and pancreatic cancer diagnostic technologies—it believes that expanding into the digital asset space is a necessary step to support long-term growth and enhance shareholder value.
Liminatus is a clinical-stage biopharmaceutical company dedicated to developing immunotherapies for cancer patients. The company is advancing a range of novel therapies targeting cancer antigens and tumor-specific immune responses.
链捕手ChainCatcher nhắc nhở: hãy nhìn nhận blockchain một cách tỉnh táo, nâng cao ý thức rủi ro, cảnh giác với việc phát hành và đầu cơ các token ảo. Mọi nội dung trên trang chỉ là thông tin thị trường hoặc quan điểm của các bên liên quan, không cấu thành bất kỳ hình thức tư vấn đầu tư nào. Nếu phát hiện nội dung nhạy cảm, hãy nhấp , chúng tôi sẽ xử lý kịp thời.







